The subthalamic nucleus (STN) has been shown to play an important role in the control of movement and has been considered as a key structure in the functional organization of the basal ganglia. Several studies postulated that the STN plays a critical role in the pathophysiology of Parkinson's disease and that its inhibition or its lesioning can reverse the cardinal motor symptoms. Nevertheless, the beneficial effect was accompanied by dyskinetic abnormal movements. In order to avoid unpleasant and irreversible side effects we used high-frequency stimulation (HFS) of the STN instead of lesions. We have shown that parkinsonian motor symptoms, akinesia, rigidity, and tremor can be alleviated by HFS of the STN in the nonhuman primate model. Side effects were controllable and appeared only at intensities higher than that inducing the improvement of motor symptoms. In severe parkinsonian patients, bilateral STN-HFS greatly improved parkinsonian motor symptoms. Motor fluctuations were attenuated and patients became independent in most activities of daily living. It appears that STN-HFS mimics the effects of lesions by inhibiting its neuronal activity. In a rat model of parkinsonism, we studied the implication of the STN in the excitotoxicity of nigral dopamine cells. We showed that kainic acid lesioning of the STN can protect nigral dopaminergic cells against 6-hydroxydopamine-induced toxicity. The evidence reviewed in the present article clearly demon strates that the STN is implicated in the pathophysiology and pathogenesis of Parkinson's disease.
INTRODUCTION
The subthalamic nucleus (STN) is a small structure of the basal ganglia characterized by a high neuronal density. Its neurons are excitatory and use glutamate as a neurotransmitter (77) . Several anatomical and electro physiological studies have shown that the STN receives excitatory glutamatergic projections from the cortex (43, 46, 66, 71) and parafascicular nucleus of the thalamus (61) , inhibitory GABAergic afferents from the external part of the globus pallidus (GPe) (1), dopaminergic pro jections from the pars compacta of the substantia nigra (SNc) (23, 56) , and cholinergic/glutamatergic afferent projections from the pedunculopontine nucleus (PPN) [for review see (66) ]. Concerning its efferents, STN neu rons project to different structures according to a spe cific topography (66) . Neurons in the associative part of the STN send efferents to the caudate nucleus of the striatum and to the main output structures of the basal ganglia (66) : the internal part of the globus pallidus (GPi) and the pars reticulata of the substantia nigra (SNr). The sensorimotor territory of the nucleus projects to the putamen and GPe and the limbic part sends pro jections to the ventral globus pallidus (GPv).
The STN has been shown to play an important role in the control of movement. It has been linked with hemiballismus, because vascular accidents in the region including STN were often associated with the appear ance of abnormal involuntary movements (AIM) (22, 54, 57, 85) . These AIMs can be reproduced in a nonhuman primate by inhibiting STN activity after in situ injection of GABA agonists or after lesion of the nucleus (26, 36, 85, 86) . Recently, several studies have demon strated that the STN is implicated in the pathophysiol ogy of Parkinson's disease.
THE PLACE OF STN IN BASAL GANGLIA CIRCUITRY
The STN has been considered as a key structure in the functional organization of the basal ganglia. Its place in basal ganglia circuitry has been recently reviewed by Parent and Hazrati (66) . In the current accepted model of this circuitry, the striatum and the STN are the two major structures through which cortical signals are trans mitted to the output nuclei of the basal ganglia (1, 66) .
The striatum and the STN receive direct excitatory glu tamatergic projections from the cortex and exert oppo-site effects, inhibitory versus excitatory, on the GPi and SNr, because they receive inhibitory GABAergic projec tions from the striatum and excitatory glutamatergic inputs from the STN. In the current model, the STN is viewed as a relay nucleus because, in addition to the direct cortico-STN pathway, the cortex influences the STN through an indirect pathway involving the striatum and GPe. Elec trophysiological studies have shown that the STN plays an important role in maintaining tonic activity in the output structures of the basal ganglia (34, 70) .
IMPLICATION OF STN IN THE PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
The manifestation of parkinsonian motor symptoms In MPTP-treated monkeys several studies have shown a significant reduction in 2-deoxyglucose uptake (60) and a significant increase in cytochrome oxidase mRNA and GAD mRNA expression at the STN level (32, 84) . Simi lar results were obtained in STN efferent structures (GPi and SNr), showing that these abnormalities can be re versed by levodopa treatment or STN lesion (32, 39) .
From these results, it has been postulated that the STN plays a critical role in the pathophysiology of Parkin son's disease and that its inhibition can be effective in the therapy of the disease.
REVERSAL OF EXPERIMENTAL PARKINSONISM BY STN INACTIVATION
Recently, pharmacological interruption of transmis sion between STN efferents and their target neurons has been shown to alleviate parkinsonian motor symptoms in experimental MPTP-treated monkeys (20, 31) . In the same animal model and under similar conditions an STN lesion has been shown to reverse the symptoms (2, 16) .
Nevertheless, this beneficial effect was accompanied by the appearance of abnormal dyskinetic movements. In addition, in the 6-OHDA rat model of parkinsonism, it has been shown that lesions of the STN reduce contralat eral rotational behavior induced by apomorphine (21) and reverse increases of reaction time, but at the same time induce multiple deficits in attention tasks (3, 4) . In the 6-OHDA-lesioned marmoset, an additional unilateral lesion of the STN significantly reversed some, but not all, parkinsonian-like deficits (38) . Animals showed a decrease of contralateral hemineglect as evidenced by improved latencies to initiate reaching on the contralat eral side on the staircase reaching task; however, deficits in skilled movements persisted. From these data it ap pears that abnormal STN activity is implicated in the manifestation of parkinsonian motor symptoms, but that lesioning of the STN may not be appropriate as a ther apy for Parkinson's disease.
In order to avoid unpleasant and irreversible side ef fects of STN lesions, we used high-frequency stimula tion (HFS) (frequency: 130 Hz, pulse width: 0.06 ms, variable intensities) of this nucleus. This technique is known to induce reversible, gradual, and controllable functional impairment of another brain structure, the ventral intermediate nucleus of the thalamus (VIM). In clinical practice, HFS (>100 Hz) applied to the VIM in duces a dramatic suppression of rest tremor in parkinso nian patients (6, 7, 9) without the adverse effects ob served after standard thalamotomy (64, 81) . Recently, we have shown that parkinsonian motor symptoms, akine sia, and rigidity can be alleviated by HFS of the STN (STN-HFS) in monkeys rendered hemiparkinsonian by unilateral intracarotid injection of MPTP (13, 14) . In these experiments, we used electromyographic record ings and comparisons of kinetic parameters in trained movements to quantify the impairment induced by the unilateral nigral lesion and the improvement obtained using STN-HFS. A clear decrease in muscle EMG re corded from agonist/antagonist muscles correlated with the decrease in clinical rigidity. Moreover, the animals were able to perform rapid trained flexion and extension movements as in the normal situation, whereas the movements performed before STN stimulation were much smaller (13, 14) . The amelioration of movement parameters was associated with the normalization of EMG activities recorded in the agonist/antagonist mus cles. In addition, the reversal of rigidity and improve ment in motor performance induced by STN-HFS were comparable to those obtained after L-dopa treatment (13) . These studies were carried out in rhesus monkeys, which developed only akinesia and rigidity after MPTP treatment, but parkinsonian rest tremor has never been observed in this species of primate (12) . To study the effect of STN-HFS on tremor we used another animal model obtained by lesioning the red nucleus and the SNc. The tremor obtained has a frequency close to that observed in parkinsonian patients, and can be sup pressed by apomorphine treatment. In this model, STN-HFS induced a dramatic arrest of rest tremor (30) . Side effects were controllable and appeared only at intensities higher than that inducing the improvement of motor symptoms. The beneficial effects of STN-HFS obtained in MPTP-treated monkeys and experience with VIM stimulation led us to propose STN-HFS for the improve ment of the whole parkinsonian triad. 
STN-HFS IN PARKINSONIAN PATIENTS

HOW DOES STN-HFS WORK?
Regarding the functional mechanism of STN-HFS, it appears from different studies that STN stimulation at high frequency mimics the effects of lesions in MPTPtreated monkeys (13, 14, 16) 
STN AND THE PATHOGENESIS OF DOPAMINERGIC CELL LOSS IN PARKINSONISM
The that was reversed by NMDA receptor antagonists (24, 25) . chemical results showed a reduction of dopamine con centration at the striatal level that was similar to that found in 6-OHDA control rats (69) . The quantification of TH-ir cell loss in SNc and dopamine concentration in the striatum was realized in animals killed 15 days after 6-OHDA infusion. Similar results were reported in other studies carried out in MPTP-treated mice previously treated with NMDA antagonists (53) or nimodipine, a selective calcium channel blocker (47) . In another ex periment, STN ablation has been shown to prevent transneuronal degeneration of SNr neurons (72) . 
